Dendritic cells pulsed with α-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1420-1426

  Ren, Jun ^a   Jia, Jun ^a   Zhang, Hongmei ^b   Zhang, Liwang ^b   Ma, Bo ^a   Jiang, Hanfang ^a   Di, Lijun ^a   Song, Guohong ^a   Yu, Jing ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; DOXORUBICIN; ENHANCED GREEN FLUORESCENT PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; LIPOSOME; PACLITAXEL; PROTEIN P53;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN HEPG2; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIVER CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ALPHA-FETOPROTEINS; ARTIFICIAL GENE FUSION; CELL LINE, TUMOR; DENDRITIC CELLS; GENES, P53; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOTHERAPY; LIPOSOMES; LIVER NEOPLASMS; MUTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 44449176727     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00820.x     Document Type: Article

References (50)

1. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7.
2. Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma. Am J Surg 1997; 173: 358-65.
3. Fuster J, Charco R, Llovet JM et al. Liver transplantation in hepatocellular carcinoma. Transpl Int 2005; 18: 278-82.
4. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179-88.
5. Su H, Chang JC, Xu SM et al. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 1996; 7: 463-70.
6. Habib NA, Ding SF, El-Masry R et al. Preliminary report: The short-term effects of direct P53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 1996; 20: 103-7.
7. Bui LA, Butterfield LH, Kim JY et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther 1997; 8: 2173-82.
8. William KD, Dongxia X, Elizabeth JS. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant 2006; 12: 113-25.
9. Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-88.
10. Holtl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8: 3369-76.
11. Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167: 7150-6.
12. Ladhams A, Schmidt C, Sing G et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17: 889-96.
13. Maier T, Tun-Kyi A, Tassis A et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003; 102: 2338-44.
14. Morisaki T, Matsumoto K, Onishi H et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: Rationale, current progress, and perspectives. Hum Cell 2003; 16: 175-82.
15. Kruger T, Schoor O, Lemmel C et al. Lessons to be learned from primary renal cell carcinomas: Novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2005; 54: 826-36.
16. McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br J Haematol 2003; 123: 770-81.
17. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171-7.
18. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002; 99: 1517-26.
19. Stevenson FK, Rice J, Zhu D. Tumor vaccines. Adv Immunol 2004; 82: 49-103.
20. Murphy GP, Tjoa BA, Simmons SJ et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38: 73-8.
21. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000; 97: 2715-18.
22. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60: 1028-34.
23. Ribas A, Butterfield LH, Hu B et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23: 59-66.
24. Reichardt VL, Brossart P, Kanz L et al. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev 2004; 18: 235-43.
25. Liao X, Li Y, Bonini C et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 2004; 9: 757-64.
26. Oh ST, Kim CH, Park MY et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006; 24: 2860-8.
27. Johnson PJ. Role of α-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14: S32-6.
28. Butterfield LH, Ribas A, Meng WS et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003; 9: 5902-8.
29. Svane IM, Pedersen AE, Johnsen HE et al. Vaccination with P53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: Report from a phase I study. Cancer Immunol Immunother 2004; 53: 633-41.
30. Zhang L, Zhang H, Liu W et al. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA. Cell Immunol 2005; 238: 61-6.
31. Zhang HM, Zhang LW, Ren J, Fan L, Si XM, Liu WC. Induction of α-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells. Cell Immunol 2006; 239: 144-50.
32. Zhang HM, Zhang LW, Liu WC, Cheng J, Si XM, Ren J. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 2006; 8: 580-8.
33. + hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses. Cell Immunol 2006; 240: 14-21.
34. Vollmer CM Jr, Eilber FC, Butterfield LH et al. α-Fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59: 3064-7.
35. Butterfield LH, Meng WS, Koh A et al. T cell responses to HLA-A*0201-restricted peptides derived from human α-fetoprotein. J Immunol 2001; 166: 5300-8.
36. Barfoed AM, Petersen TR, Kirkin AF, Thor SP, Claesson MH, Zeuthen J. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding P5365-73 wild type peptide loaded on dendritic cells in vitro, specially recognize and lyse HLA-A2 tumour cells overexpressing the P53 protein. Scand J Immunol 2000; 51: 128.
37. Ropke M, Hald J, Guldberg P et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type P53-derived peptide. Proc Natl Acad Sci USA 1996; 93: 14704.
38. Wurtzen PA, Claesson MH. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed P53 epitope. Int J Cancer 2002; 99: 568.
39. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH. Identication and design of P53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001; 53: 357.
40. Nikitina EY, Clark JI, van Beynen J et al. Dendritic cells transduced with full-length wild-type P53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001; 7: 127-35.
41. Schreiber H. Wu TH, Nachman J, and Kast WM. Immunodominance and tumor escape. Semin Cancer Biol 2002; 12: 25.
42. Palmowski MJ, Choi EM, Hermans IF et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002; 168: 4391.
43. Paquette RL, Hsu NC, Kiertscher SM et al. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64: 358-67.
44. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Meth 1996; 196: 121-35.
45. Cao H, Verge V, Baron C et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res 2000; 9: 183-94.
46. Vuillier F, Maloum K, Thomas EK, Jouanne C, Dighiero G, Scott-Algara D. Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 831-44.
47. Miller G, Lahrs S, Pillarisetty VG, Shah BA, DeMatteo PR. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 5260-6.
48. + dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther 2000; 7: 249-54.
49. U'Ren L, Kedl R, Dow S. Vaccination with liposome -DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther 2006; 13 (11): 1033-44.
50. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 2006; 23: 385-95.